Annovis Bio: notice of delisting or failure to meet a listing standard

Form 8-K filed Oct 30, 2026 · items 3.01, 7.01

Delisting noticesANNOVIS BIO, INC. RECEIVES CONTINUED

What the filing says

On October 29, 2026, Annovis Bio, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average mar

Read the filing on SEC EDGAR →

What usually followsAcross 492 8-Ks reporting Item 3.01 (delisting notice or listing-rule failure) in our universe, the stock's median move the next session was 0.0% (typical size ±2.1%, up 46% of the time); over the following 21 sessions, −0.2%. Every item ranked →

What this kind of filing means

Item 3.01 — Notice of delisting or failure to meet a listing standard. A delisting notice starts a compliance window; companies often answer with a reverse split, a plan, or a move to another market.

Annovis Bio’s other material 8-Ks

Nov 5, 2026 — Share offerings Annovis Announces Launch of Proposed Public Offering

Other recent delisting notices

Barfresh Food Group Nov 6, 2026
Fifth Era Acquisition Corp I Nov 6, 2026
Tempest Therapeutics Nov 6, 2026
Roku Nov 6, 2026
Bowman Consulting Group Nov 6, 2026
Knightscope Nov 6, 2026
Curis Nov 6, 2026
Intrusion Nov 5, 2026
Karyopharm Therapeutics Nov 5, 2026
Cognition Therapeutics Nov 5, 2026

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.